ALX Oncology Holdings Inc (ALXO)

Etorro trading 970x250
ALX Oncology Holdings Inc (ALXO) Logo

About ALX Oncology Holdings Inc

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company’s pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California. Address: 866 Malcolm Road, Burlingame, CA, United States, 94010

ALX Oncology Holdings Inc News and around…

Latest news about ALX Oncology Holdings Inc (ALXO) common stock and company :

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
16 Aug, 2022 Yahoo! Finance

ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative™ ("Quantum Leap") today announced that ALX Oncology's next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Qua

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
11 Aug, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ: RDUS), New Drug ...

ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off
11 Aug, 2022 FinancialContent

ALX Oncology Holdings (NASDAQ: ALXO) has initiated a Phase 2 investigator-sponsored study of evorpacept in combination with Eli ...

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
11 Aug, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with ERBITUX® (cetuximab) and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with refractory microsatellite stable metas

Analysts See 17% Gains Ahead For The Holdings of IWV
10 Aug, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $279.38 per unit.

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
08 Aug, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2022 and provided clinical development and operational highlights. “The second quarter of 2022 was marked by substantial progress advancing our lead program, evorpacept, through multiple clinical trials,”

Recap Of Monday's Biotech Catalysts - End Of the Day Summary
01 Aug, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ: ELDN) Investigational New Drug ...

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
01 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Arcutis Psoriasis Treatment ...

ALX Oncology Shares Gain As FDA Grants Fast Track Status To Head And Neck Cancer Candidate
01 Aug, 2022 FinancialContent

ALX Oncology Holdings (NASDAQ: ALXO) receives Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead asset ...

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
01 Aug, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to evorpacept, a next generation CD47 blocker, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the first-line treatment of adult patients with

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
28 Jul, 2022 FinancialContent

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. TAC-001 is the company’s lead clinical candidate from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform and the first to enter the clinic.

12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Jul, 2022 FinancialContent

Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their ...

How The Parts Add Up: IWV Headed For $293
07 Jul, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $293.10 per unit.

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
29 Jun, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eli Lilly To Supply ...

ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate
29 Jun, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) ...

ALX's stock is up 11% after getting orphan-drug designation for cancer drug
29 Jun, 2022 Yahoo! Finance

Shares of ALX Oncology Holdings Inc. gained 11.5% in premarket trading on Wednesday after the company said it received an orphan-drug designation for evorpacept, its experimental acute myeloid leukemia therapy. This designation is granted to drugs that treat diseases or conditions that affect fewer than 200,000 people in the U.S. ALX's stock has declined 62.5% so far this year, while the broader S&P 500 is down 19.8%.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Jun, 2022 FinancialContent

Gainers Allena Pharma (NASDAQ:ALNA) stock moved upwards by 83.2% to $0.22 during Wednesday's pre-market session. The ...

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
29 Jun, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with acute myeloid leukemia (“AML”). “Receiving orphan drug designation in AML, and previou

Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
22 Jun, 2022 Yahoo! Finance

SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of an abstract presenting data on the autonomous triggering and injection efficiency of its systemic therapeutics delivery system by the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference. This meeting explores the latest technological advances in the drug delivery devices arena a

Stocks That Hit 52-Week Lows On Monday
06 Jun, 2022 FinancialContent

Monday's session saw 84 companies set new 52-week lows. Facts of Interest About Today's 52-Week ...

ALX Oncology Announces Evorpacept Clinical Program Updates
03 Jun, 2022 Yahoo! Finance

– Expansion of solid tumor clinical program– ASPEN-02 dose optimization data to inform dosing for ASPEN-05 SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced clinical program updates for its lead program, evorpacept, a next generation CD47 blocker. Introducing ASPEN-07, a Phase 1 Trial of Evorpacept for the T

ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
01 Jun, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2022 Healthcare Conference on Wednesday, June 8 at 10:00 am ET in New York. A live webcast of the fireside chat is available here and

Stocks That Hit 52-Week Lows On Tuesday
31 May, 2022 FinancialContent

On Tuesday, 36 companies achieved new lows for the year. Things to Consider About Today's 52-Week Lows: The ...

Buying Power of Bitcoin vs. ALX Oncology Holdings at New 52-Week High
20 May, 2022 FinancialContent

Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.

Analysts See 31% Gains Ahead For The Holdings of PBSM
05 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.13 per unit.

Noteworthy Friday Option Activity: ALXO, X, GS
29 Apr, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ALX Oncology Holdings Inc (ALXO), where a total volume of 1,771 contracts has been traded thus far today, a contract volume which is representative of approximately 177,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 58.1% of ALXO's average daily trading volume over the past month, of 304,670 shares..

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
12 Apr, 2022 Yahoo! Finance

Itziar Canamasas, Ph.D. ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the “Board”) effective April 11, 2022. With more than 20 years of biopharmaceutical indust

Notable Monday Option Activity: BAC, VAC, ALXO
11 Apr, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Bank of America Corp (BAC), where a total volume of 216,858 contracts has been traded thus far today, a contract volume which is representative of approximately 21.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.3% of BAC's average daily trading volume over the past month, of 50.1 million shares..

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer
02 Mar, 2022 Yahoo! Finance

Phase 2/3 study initiated in collaboration with Eli Lilly and CompanySOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the first patient has been dosed in the Phase 2/3 ASPEN-06 study evaluating the combination of evorpacept, a next generation CD47 blocker, and CYRAMZA® (ramucirumab), Eli Lilly and Compa

ALX Oncology Holdings: Q4 Earnings Insights
28 Feb, 2022 FinancialContent

ALX Oncology Holdings (NASDAQ:ALXO) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's ...

ALX Oncology Holdings Inc (ALXO) is a NASDAQ Common Stock listed in , ,

970x250